Affymetrix Signs Three-Year Translational Medicine Agreement With Vanderbilt-Ingram Cancer Center

Research Team to Use Affymetrix GeneChip(R) Technology to Develop Applications for Cancer and HIV/AIDS

26-Jan-2007

Affymetrix Inc. and Vanderbilt-Ingram Cancer Center announced that they have entered into a three-year translational research collaboration to analyze genomic information across a large number of patient samples. Under terms of the agreement, researchers at Vanderbilt-Ingram and Vanderbilt University Medical Center will use Affymetrix GeneChip(R) microarray technology to develop new applications for translational research projects, focusing on disease areas such as cancer and HIV/AIDS. The HIV/AIDS translational research project will aim to help clinicians avoid the often irreversible and costly complications of therapy. The results of this study will potentially help clinicians select the most appropriate drug therapy for each patient, avoiding those most likely to cause toxicity. Such a tool could have important applications for HIV/AIDS treatment in both affluent and resource-limited settings, and for other diseases.

"A number of important translational projects are underway, ranging from cancer research to HIV/AIDS drug toxicities to age-related macular degeneration," said Jeff Canter M.D., M.P.H., assistant professor of molecular physiology and biophysics at the Center for Human Genetics Research at Vanderbilt University Medical Center. "This is a very exciting time because new sequencing technologies allow us to explore real-world applications of discoveries from the revolution in genetics that until now have been confined to the laboratory."

https://www.bionity.com/en/news/61248/affymetrix-signs-three-year-translational-medicine-agreement-with-vanderbilt-ingram-cancer-center.html